Vadodara News Flash

Prostate Cancer Epidemiology Forecast to 2030 by DelveInsight

 Breaking News
  • No posts were found

Prostate Cancer Epidemiology Forecast to 2030 by DelveInsight

February 24
19:45 2021
Prostate Cancer Epidemiology Forecast to 2030 by DelveInsight

 

DelveInsight has launched a new report on Prostate Cancer Epidemiology

 

 

Prostate cancer is a type of malignancy that occurs in the prostate gland, which is a part of male reproductive system. Prostate cancer is the 3rdmost prevalent type of cancer in the US and the fourth most common worldwide.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/prostate-cancer-epidemiology-forecast

 

The Prostate Cancer Epidemiology Report covers the overview, treatment practice and forecasted epidemiology of Prostate Cancer Epidemiology from 2020 to 2030

 

Prostate Cancer Epidemiology

According to the Cancer Treatment Centers of America (CTCA), more than 99% of prostate cancers are adenocarcinomas, which develop in the gland cells. It is common in men of 50–64 years and over age 65; however, it can occur in men younger than 50 years. Symptoms of adenocarcinoma of the prostate include blood in the semen, frequent urge to urinate, and painful urination and ejaculation.

 

Key facts of Prostate Cancer Epidemiology

  • The total prevalent cases of Prostate Cancer in the 7MM were observed to be 6,742,385 cases in 2017, and are expected to increase during the study period (2017–2030).
  • The highest number of prevalent cases was observed in the United States with 3,170,339 cases in 2017 which will increase during the study period (2017–2030).
  • According to DelveInsight’s analysis, nearly 60 percent of Prostate Cancer cases diagnosed during localized or locally advanced stage (Stage I-III) in the United States

 

Prostate Cancer Epidemiology Segmentation

  • Total Prevalent Cases of Prostate Cancer in the 7MM [2017–2030]
  • Age-Specific Cases of Prostate Cancer in the 7MM [2017–2030]
  • Total Non-Metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the 7MM [2017–2030]
  • Total Treated Cases of mHSPC/CSPC and and CRPC in the 7MM [2017–2030]
  • Total Diagnosed Cases of Prostate Cancer in the 7MM [2017–2030]
  • Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages in the 7MM [2017–2030]
  • Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC in the 7MM [2017–2030]

 

Prostate Cancer Epidemiology Report Scope

• The Prostate Cancer report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.

• The Prostate Cancer Report and Model provide an overview of the risk factors and global trends of Prostate Cancer in the seven major markets (7MM: United States, Germany, France, Italy, Spain, and the United Kingdom, and Japan).

• The report provides insight about the historical and forecasted patient pool of Prostate Cancer in seven major markets covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.

• The report assesses the disease risk and burden and highlights the unmet needs of Prostate Cancer.

• The report provides the segmentation of the Prostate Cancer epidemiology by total prevalent cases of Prostate Cancer in the 7MM.

• The report provides the segmentation of the Prostate Cancer epidemiology by total diagnosed prevalent cases of Prostate Cancer in the 7MM.

• The report provides the segmentation of the Prostate Cancer epidemiology by total diagnosed cases of Prostate Cancer patients by clinical stages in the 7MM.

• The report provides the segmentation of the Prostate Cancer epidemiology by Age-specific Cases in the 7MM.

• The report provides the segmentation of the Prostate Cancer epidemiology by Non-metastatic and Metastatic Cases of CSPC/HSPC and CRPC in the 7MM.

• The report provides the segmentation of the Prostate Cancer epidemiology by Treated cases of Non-metastatic CSPC/HSPC and CRPC in the 7MM.

• The report provides the segmentation of the Prostate Cancer epidemiology by Treated Cases of mHSPC/CSPC in the 7MM.

 

Request for free sample copy- https://www.delveinsight.com/sample-request/prostate-cancer-epidemiology-forecast

 

Table of content

1. Key Insights

2. Executive Summary of Prostate Cancer

3. Prostate Cancer: Disease Background and Overview

4. Diagnosis of Prostate Cancer

5. Epidemiology and Patient Population

6. EU-5 Country-wise Epidemiology

7. Appendix

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

 

What are the reasons to buy?

• Develop business strategies by understanding the trends shaping and driving the global Prostate Cancer market

• Quantify patient populations in the global Prostate Cancer market to improve product design, pricing, and launch plans

• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Prostate Cancer therapeutics in each of the markets covered

• Understand the magnitude of Prostate Cancer population by its severity

• The Prostate Cancer epidemiology report and model were written and developed by Masters and PhD level epidemiologists

• The Prostate Cancer Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles